Mariaelena Pierobon

12PUBLICATIONS
64CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 09, 2026
Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling.

|Jun 08, 2026
The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

|Jul 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.

Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp

|Sep 25, 2024
Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.

Deepika Prasad, Elisa Baldelli, Edik M Blais

|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.

Daniel P Nussbaum, Colin A Martz, Andrew M Waters

|May 06, 2024
Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.

Nicholas W Bateman, Tamara Abulez, Anthony R Soltis

Pageof 2

Frequent Collaborators

4 joint publications

Channing J Der

3 joint publications

Elisa Baldelli

3 joint publications

Andrew Waters

3 joint publications

Emanuel F Petricoin